FDA Hits Two More Asian Firms With Drug GMP Warning Letters
Executive Summary
The spate of recent warning letters going to foreign pharmaceutical manufacturers continues as two Asian firms get into trouble for GMP violations: Firson Co. in South Korea and Wuxi Medical Instrument Factory in China.
You may also be interested in...
Lost In Translation: Rx Drug Used Where OTC Hydrocortisone Belongs
In a "translation mistake," Zhanjiang Jimin Pharmaceutical's management "thought hydrocortisone was the same material as dexamethasone," FDA says. The China firm's product, distributed in the US by Lucky Mart Inc. under the brand Piyanping Anti-Itch Lotion, is being recalled.
Lost In Translation: Rx Drug Used Where OTC Hydrocortisone Belongs
In a "translation mistake," Zhanjiang Jimin Pharmaceutical's management "thought hydrocortisone was the same material as dexamethasone," FDA says. The China firm's product, distributed in the US by Lucky Mart Inc. under the brand Piyanping Anti-Itch Lotion, is being recalled.
FDA GMP Warning Letters Review: Rate Soared In 2016 On Sterility And Data Integrity Concerns
Poor data integrity at Asian API firms, poor quality programs at foreign OTC firms and poor sterility assurance at US compounding pharmacies were the main factors leading US FDA to issue 110 drug GMP warning letters in 2016, a huge increase from prior years. Article is first of four-part series in our annual analysis.